{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:20:32Z","timestamp":1790958032943,"version":"4.1.0"},"reference-count":122,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1097\/nrl.0b013e31823968fc","type":"journal-article","created":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T07:43:34Z","timestamp":1320133414000},"page":"S54-S66","source":"Crossref","is-referenced-by-count":22,"title":["Neuroprotective Role of Dopamine Agonists"],"prefix":"10.1097","volume":"17","author":[{"given":"Maria Trinidad","family":"Herrero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pagonabarraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurutz","family":"Linazasoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210211","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ageing\/afp223","article-title":"Ageing, neurodegeneration and Parkinsons Disease Ageing, neurodegeneration and Parkiknsons disease.","volume":"39","author":"Hindle","year":"2010","journal-title":"Age Ageing"},{"key":"R2-11-20210211","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinsons disease.","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol Aging"},{"key":"R3-11-20210211","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1750-3639.2002.tb00452.x","article-title":"Mechanisms of cell death in neurodegenerative diseases: fashion, fiction, and facts.","volume":"12","author":"Graeber","year":"2002","journal-title":"Brain Pathol"},{"key":"R5-11-20210211","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.nbd.2009.11.004","article-title":"Neuroinflammation in Parkinsons disease: its role in neuronal death and implications for therapeutic intervention.","volume":"37","author":"Tansey","year":"2010","journal-title":"Neurobiology Dis"},{"key":"R6-11-20210211","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.molmed.2009.11.004","article-title":"Pathogenesis of Parkinsons disease: emerging role of molecular chaperones.","volume":"16","author":"Bandopadhyay","year":"2009","journal-title":"Trends Mol Med"},{"key":"R7-11-20210211","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd3430","article-title":"Priorities in Parkinsons disease research.","volume":"10","author":"Meissner","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"R9-11-20210211","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1126\/science.3306916","article-title":"The nerve growth factor 35 five years later.","volume":"237","author":"Levi-Montalcini","year":"1987","journal-title":"Science"},{"issue":"Suppl 3","key":"R11-11-20210211","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1002\/ana.10514","article-title":"Rationale for the use of dopamine agonists as neuroprotective agents in Parkinsons disease.","volume":"53","author":"Schapira","year":"2003","journal-title":"Ann Neurol"},{"issue":"Suppl 2","key":"R12-11-20210211","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1212\/WNL.0b013e3181990438","article-title":"Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinsons disease.","volume":"72","author":"Schapira","year":"2009","journal-title":"Neurology"},{"key":"R13-11-20210211","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.parkreldis.2009.02.011","article-title":"A global view of Parkinsons disease pathogenesis: Implications for natural history and neuroprotection.","volume":"15","author":"Linazasoro","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"R14-11-20210211","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ana.21778","article-title":"Dopaminergic transplantation for Parkinsons disease: current status and future prospects.","volume":"66","author":"Olanow","year":"2009","journal-title":"Ann Neurol"},{"key":"R15-11-20210211","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ana.10720","article-title":"A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinsons disease.","volume":"54","author":"Olanow","year":"2003","journal-title":"Ann Neurol"},{"key":"R16-11-20210211","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1749-6632.2009.05229.x","article-title":"Lewy body pathology in fetal grafts.","volume":"1184","author":"Chu","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"R17-11-20210211","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0079-6123(09)17514-3","article-title":"Trophic factors therapy in Parkinsons disease.","volume":"175","author":"Ramaswamy","year":"2009","journal-title":"Prog Brain Res"},{"issue":"Suppl 1","key":"R18-11-20210211","doi-asserted-by":"crossref","first-page":"S161","DOI":"10.1002\/mds.22785","article-title":"Gene therapy for Parkinsons disease.","volume":"25","author":"Bjorklund","year":"2010","journal-title":"Mov Disord"},{"issue":"1-2","key":"R19-11-20210211","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jns.2009.08.025","article-title":"Clinical neuroprotection in Parkinsons disease: still waiting for the breakthrough.","volume":"289","author":"Lohle","year":"2010","journal-title":"J Neurol Sci"},{"key":"R20-11-20210211","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/157015909787602814","article-title":"Targeting the progression of Parkinsons disease.","volume":"7","author":"George","year":"2009","journal-title":"Current Neuropharmacol"},{"key":"R22-11-20210211","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","article-title":"A double-blind, delayed-start trial of rasagiline in Parkinsons disease.","volume":"361","author":"Olanow","year":"2009","journal-title":"N Engl J Med"},{"key":"R23-11-20210211","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1749-6632.2009.05118.x","article-title":"The progression of pathology in Parkinsons disease.","volume":"1184","author":"Halliday","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"R25-11-20210211","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1185\/03007990903364954","article-title":"Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.","volume":"25","author":"Albrecht","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"R26-11-20210211","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.4161\/auto.5.8.9894","article-title":"Parkinson disease, LRRK2 and the endocytic-autophagic pathway.","volume":"5","author":"Alegre-Abarrategui","year":"2009","journal-title":"Autophagy"},{"key":"R27-11-20210211","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pneurobio.2007.10.003","article-title":"Disease-modifying drugs and Parkinsons disease.","volume":"84","author":"Allain","year":"2008","journal-title":"Prog Neurobiol"},{"key":"R28-11-20210211","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00221-006-0539-y","article-title":"Inhibitors of alpha-synuclein oligomerization and toxicity: a future therapeutic strategy for Parkinsons disease and related disorders.","volume":"173","author":"Amer","year":"2006","journal-title":"Exp Brain Res"},{"key":"R29-11-20210211","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.2174\/138161208784480153","article-title":"Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and Parkinsons disease.","volume":"14","author":"Asanuma","year":"2008","journal-title":"Curr Pharm Des"},{"key":"R30-11-20210211","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.pnpbp.2009.07.018","article-title":"Modulation of brain-derived neurotrophic factor as potential neuroprotective mechanism of action of omega-3 fatty acids in a parkinsonian animal model.","volume":"33","author":"Bousquet","year":"2009","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R31-11-20210211","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.tins.2007.03.009","article-title":"Multiple hit hypothesis for dopamine neuron loss in Parkinsons disease.","volume":"30","author":"Sulzer","year":"2007","journal-title":"Trends Neurosci"},{"key":"R32-11-20210211","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/humu.21277","article-title":"Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update.","volume":"31","author":"Nuytemans","year":"2010","journal-title":"Hum Mutat"},{"key":"R33-11-20210211","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.neuron.2010.04.034","article-title":"Genetic animal models of Parkinsons disease.","volume":"66","author":"Dawson","year":"2010","journal-title":"Neuron"},{"key":"R34-11-20210211","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.pneurobio.2009.11.001","article-title":"Parkinsons disease: exit toxins, enter genetics.","volume":"90","author":"Westerlund","year":"2010","journal-title":"Prog Neurobiol"},{"key":"R35-11-20210211","doi-asserted-by":"crossref","first-page":"7308","DOI":"10.1021\/jm800210c","article-title":"Multi-target-directed ligands to combat neurodegenerative diseases.","volume":"51","author":"Cavalli","year":"2008","journal-title":"J Med Chem"},{"key":"R37-11-20210211","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1111\/j.1471-4159.2009.06074.x","article-title":"Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinsons and Huntingtons diseases.","volume":"109","author":"Yang","year":"2009","journal-title":"J Neurochem"},{"issue":"Suppl 3","key":"R38-11-20210211","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1016\/S1353-8020(09)70812-0","article-title":"Therapeutic approaches to mitochondrial dysfunction in Parkinsons disease.","volume":"15","author":"Beal","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"R39-11-20210211","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bbr.2008.09.040","article-title":"Minocycline and neurodegenerative diseases.","volume":"196","author":"Kim","year":"2009","journal-title":"Behav Brain Res"},{"issue":"Suppl 1","key":"R40-11-20210211","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.expneurol.2004.08.021","article-title":"Ubiquitin-proteasome system and Parkinsons diseases.","volume":"191","author":"Betarbet","year":"2005","journal-title":"Exp Neurol"},{"key":"R41-11-20210211","first-page":"699","article-title":"Molecular characterization of dopamine-derived quinones reactivity toward NADH and glutathione: Implications for mitochondrial dysfunction in Parkinson disease.","volume":"1802","author":"Bisaglia","year":"2010","journal-title":"Biochem Biophys Acta"},{"key":"R42-11-20210211","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.nbd.2009.09.024","article-title":"Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration.","volume":"37","author":"Zhu","year":"2010","journal-title":"Neurobiol Dis"},{"key":"R43-11-20210211","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1021\/jm901618d","article-title":"Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2D3 agonists and as iron chelator: in vivo activity indicates potential application in symptomatic and neuroprotective therapy for Parkinsons disease.","volume":"53","author":"Ghosh","year":"2010","journal-title":"J Med Chem"},{"key":"R44-11-20210211","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.pneurobio.2010.06.008","article-title":"Rasagiline: a novel anti-parkinsonian monoamine oxidase-b inhibitor with neuroprotective activity.","volume":"92","author":"Weinreb","year":"2010","journal-title":"Prog Neurobiol"},{"key":"R45-11-20210211","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1038\/nrneurol.2010.31","article-title":"Parkinson disease: calcium channel blockers and Parkinson disease.","volume":"6","author":"Pfeiffer","year":"2010","journal-title":"Nat Rev Neurol"},{"key":"R46-11-20210211","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ceca.2009.12.003","article-title":"Calcium, cellular aging, and selective neuronal vulnerability in Parkinsons disease.","volume":"47","author":"Surmeier","year":"2010","journal-title":"Cell Calcium"},{"key":"R47-11-20210211","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1353-8020(01)00040-2","article-title":"A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinsons disease.","volume":"8","author":"Jankovic","year":"2002","journal-title":"Parkinsonism Relat Disord"},{"key":"R48-11-20210211","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1124\/jpet.109.158436","article-title":"Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity.","volume":"332","author":"Putcha","year":"2010","journal-title":"Pharmacol Exp Ther"},{"key":"R49-11-20210211","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1756-6606-1-17","article-title":"Lysosomal enzyme cathepsin D protects against alpha-synuclein aggregation and toxicity.","volume":"1","author":"Qiao","year":"2008","journal-title":"Mol Brain"},{"key":"R50-11-20210211","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of alpha-synuclein immunization in a mouse model of Parkinsons disease.","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron"},{"key":"R52-11-20210211","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/nn.2575","article-title":"Autophagy gone awry in neurodegenerative diseases.","volume":"13","author":"Wong","year":"2010","journal-title":"Nat Neurosci"},{"key":"R53-11-20210211","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1471-4159.2011.07314.x","article-title":"Autophagy deregulation in neurodegenerative diseases-recent advances and future perspectives.","volume":"118","author":"Cheung","year":"2011","journal-title":"J Neurochem"},{"key":"R55-11-20210211","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1385\/JMN:24:3:425","article-title":"Pathological proteins in Parkinsons disease: focus on the proteasome.","volume":"24","author":"Snyder","year":"2004","journal-title":"J Mol Neurosci"},{"key":"R56-11-20210211","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.1111\/j.1742-4658.2009.07343.x","article-title":"LRRK2 in Parkinsons disease: in vivo models and approaches for understanding pathogenic roles.","volume":"276","author":"Yue","year":"2009","journal-title":"FEBS J"},{"key":"R57-11-20210211","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/bjc.1972.33","article-title":"Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics.","volume":"26","author":"Kerr","year":"1972","journal-title":"Br J Cancer"},{"key":"R58-11-20210211","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1146\/annurev.pharmtox.47.120505.105122","article-title":"Mitochondrial oxidative stress: implications for cell death.","volume":"47","author":"Orrenius","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R59-11-20210211","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.yexcr.2010.02.037","article-title":"Cell death mechanisms: cross-talk and role in disease.","volume":"316","author":"Zhivotovsky","year":"2010","journal-title":"Exp Cell Res"},{"key":"R60-11-20210211","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1017\/S1462399410001456","article-title":"Mitochondrial quality control and neurological disease: an emerging connection.","volume":"19","author":"De Castro","year":"2010","journal-title":"Exprt Rev Mol Med"},{"key":"R61-11-20210211","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.cell.2010.02.016","article-title":"Mechanisms underlying inflammation in neurodegeneration.","volume":"140","author":"Glass","year":"2010","journal-title":"Cell"},{"key":"R62-11-20210211","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/glia.20015","article-title":"Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure.","volume":"46","author":"Barcia","year":"2004","journal-title":"Glia"},{"key":"R63-11-20210211","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1212\/WNL.0b013e3181d5a4a3","article-title":"Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis.","volume":"74","author":"Gagne","year":"2010","journal-title":"Neurology"},{"key":"R64-11-20210211","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35102591","article-title":"A subset of NSAIDs lower amyloidogenic Ab42 independently of cyclooxygenase activity.","volume":"414","author":"Weggen","year":"2001","journal-title":"Nature"},{"key":"R65-11-20210211","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1007\/s11064-008-9863-x","article-title":"Reduction of nuclear peroxisome proliferator-activated receptor gamma expression in methamphetamine-induced neurotoxicity and neuroprotective effects of ibuprofen.","volume":"34","author":"Tsuji","year":"2009","journal-title":"Neurochem Res"},{"key":"R66-11-20210211","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/34184","article-title":"PPAR-c agonists inhibit production of monocyte inflammatory cytokines.","volume":"391","author":"Jiang","year":"1998","journal-title":"Nature"},{"key":"R67-11-20210211","doi-asserted-by":"crossref","first-page":"7810","DOI":"10.1523\/JNEUROSCI.15-12-07810.1995","article-title":"Implanted fibroblast genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinsons disease.","volume":"15","author":"Frim","year":"1995","journal-title":"J Neurosci"},{"key":"R68-11-20210211","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1126\/science.275.5301.838","article-title":"Dopaminergic neurons protected from degeneration by GDNF gene therapy.","volume":"275","author":"Choi-Lundberg","year":"1997","journal-title":"Science"},{"key":"R69-11-20210211","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1046\/j.1460-9568.1999.00566.x","article-title":"Protection and regeneration of nigral dopaminergic neurons by neurturin or GDNF in a partial lesion model of Parkinsons disease after administration into the striatum or the lateral ventricle.","volume":"11","author":"Rosenblad","year":"1999","journal-title":"Eur J Neurosci"},{"issue":"Suppl 3","key":"R71-11-20210211","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1046\/j.1468-1331.9.s3.9.x","article-title":"Dopamine agonists and neuroprotection in Parkinsons disease.","volume":"9","author":"Schapira","year":"2002","journal-title":"Eur J Neurol"},{"key":"R72-11-20210211","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/0197-4580(92)90048-3","article-title":"Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats.","volume":"13","author":"Felten","year":"1992","journal-title":"Neurobiol Aging"},{"issue":"Suppl 1","key":"R73-11-20210211","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1046\/j.1468-1331.2000.0070s1015.x","article-title":"Pre-clinical studies of pramipexole: clinical relevance.","volume":"7","author":"Hubble","year":"2000","journal-title":"Eur J Neurol"},{"key":"R74-11-20210211","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1471-4159.1998.71010295.x","article-title":"Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the parkinsonian neurotoxin methylpyridinium ion.","volume":"71","author":"Cassarino","year":"1998","journal-title":"J Neurochem"},{"key":"R75-11-20210211","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S0006-8993(00)02493-8","article-title":"Increase of bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole.","volume":"872","author":"Takata","year":"2000","journal-title":"Brain Res"},{"key":"R76-11-20210211","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0022-3565(24)38124-8","article-title":"Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.","volume":"289","author":"Ling","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"key":"R77-11-20210211","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1046\/j.1471-4159.2001.t01-1-00227.x","article-title":"Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss.","volume":"77","author":"Grunblatt","year":"2001","journal-title":"J Neurochem"},{"key":"R79-11-20210211","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.47.120505.105159","article-title":"Allosteric modulation of G protein-coupled receptors.","volume":"47","author":"May","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"Pt4","key":"R80-11-20210211","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1042\/BST0350733","article-title":"Mechanisms underlying agonist efficacy.","volume":"35","author":"Strange","year":"2007","journal-title":"Biochem Soc Trans"},{"issue":"1-2","key":"R81-11-20210211","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jns.2010.01.013","article-title":"The effect of dopamine agonists: the expression of GDNF, NGF, and BDNF in cultured mouse astrocytes.","volume":"291","author":"Ohta","year":"2010","journal-title":"J Neurol Sci"},{"key":"R82-11-20210211","first-page":"57","article-title":"Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity.","volume":"55","author":"Grunblatt","year":"1999","journal-title":"J Neural Transm Suppl"},{"key":"R83-11-20210211","first-page":"83","article-title":"Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine.","volume":"58","author":"Youdim","year":"2000","journal-title":"J Neural Transm Suppl"},{"key":"R84-11-20210211","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.neuropharm.2008.06.041","article-title":"Apomorphine offers new insight into dopaminergic neuron vulnerability in mesencephalic cultures.","volume":"55","author":"Vaglini","year":"2008","journal-title":"Neuropharmacology"},{"key":"R85-11-20210211","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/mds.870130409","article-title":"Apomorphine enantiomers protect cultured pheochromocytoma (PC12) cells from oxidative stress induced by H2O2 and 6-hydroxydopamine.","volume":"13","author":"Gassen","year":"1998","journal-title":"Mov Disord"},{"key":"R86-11-20210211","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0028-3908(01)00178-2","article-title":"Continuous subcutaneous infusion of apomorphine rescues nigro-striatal dopaminergic terminals following MPTP injection in mice.","volume":"42","author":"Battaglia","year":"2002","journal-title":"Neuropharmacology"},{"key":"R87-11-20210211","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1749-6632.2002.tb04167.x","article-title":"Morphological and biochemical evidence that apomorphine rescues striatal dopamine terminals and prevents methamphetamine toxicity.","volume":"965","author":"Battaglia","year":"2002","journal-title":"Ann N Y Acad Sci"},{"key":"R88-11-20210211","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1006\/bbrc.2000.2732","article-title":"Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes.","volume":"272","author":"Ohta","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"key":"R90-11-20210211","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0028-3908(03)00152-7","article-title":"Dose-dependent induction of apoptosis by R-apomorphine in CHO-K1 cell line in culture.","volume":"45","author":"Pardini","year":"2003","journal-title":"Neuropharmacology"},{"key":"R91-11-20210211","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1089\/109454503765361551","article-title":"Neuroprotective, anti-apoptotic effects of apomorphine.","volume":"6","author":"Kyriazis","year":"2003","journal-title":"J Anti Aging Med"},{"key":"R92-11-20210211","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1006\/phrs.2000.0690","article-title":"Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment.","volume":"42","author":"Finotti","year":"2000","journal-title":"Pharmacol Res"},{"key":"R93-11-20210211","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1385\/JMN\/31:02:127","article-title":"Identification of neuroprotective compounds of caenorhabditis elegans dopaminergic neurons against 6-OHDA.","volume":"31","author":"Marvanova","year":"2007","journal-title":"J Mol Neurosci"},{"key":"R94-11-20210211","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000077451","article-title":"Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture.","volume":"71","author":"Ohta","year":"2004","journal-title":"Pharmacology"},{"key":"R95-11-20210211","first-page":"325","article-title":"Bromocriptine activates NQO1 via Nrf2-PI3KAkt signalling: novel cytoprotective mechanism against oxidative damage.","volume":"57","author":"Him","year":"2009","journal-title":"Pharmacol Res"},{"key":"R96-11-20210211","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.neulet.2008.12.056","article-title":"Protective effect of bromocriptine against BH4-induced Cath.a cell death involving up-regulation of antioxidant enzymes.","volume":"451","author":"Lim","year":"2009","journal-title":"Neurosci Lett"},{"key":"R97-11-20210211","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1042\/bj20030017","article-title":"Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines.","volume":"373","author":"Nair","year":"2003","journal-title":"Biochem J"},{"key":"R98-11-20210211","doi-asserted-by":"crossref","first-page":"15469","DOI":"10.1074\/jbc.M707238200","article-title":"Differential modulation of Aktglycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses.","volume":"283","author":"Nair","year":"2008","journal-title":"Biol Chem"},{"key":"R99-11-20210211","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.febslet.2008.01.028","article-title":"D2D3 receptor agonist ropirinole protects dopaminergic cell lines against rotenone-induced apoptosis through inhibition of caspase- and JNK-dependent pathways.","volume":"582","author":"Chen","year":"2008","journal-title":"FEBS Lett"},{"key":"R100-11-20210211","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.euroneuro.2005.08.003","article-title":"Dopaminergic drugs may counteract behavioral and biochemical changes induced by models of brain injury.","volume":"16","author":"Micale","year":"2006","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1-2","key":"R101-11-20210211","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0006-8993(99)01688-1","article-title":"Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist.","volume":"838","author":"Iida","year":"1999","journal-title":"Brain Res"},{"key":"R102-11-20210211","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1023\/A:1007672414239","article-title":"Molecular mechanism in activation of glutathione system by ropinirole, a selective dopamine D2 agonist.","volume":"26","author":"Tanaka","year":"2001","journal-title":"Neurochem Res"},{"key":"R103-11-20210211","doi-asserted-by":"crossref","first-page":"15469","DOI":"10.1074\/jbc.M707238200","article-title":"Differential modulation of Aktglycogen synthase kinase-3pathway regulates apoptotic and cytoprotective signaling responses.","volume":"283","author":"Venugopalan","year":"2008","journal-title":"J Biol Chem"},{"issue":"6-7","key":"R104-11-20210211","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.bbabio.2010.02.001","article-title":"The dopamine-D2-receptor agonist ropinirole dose-dependently blocks the Ca(2)-triggered permeability transition of mitochondria.","volume":"1797","author":"Parvez","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"R105-11-20210211","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0022-3565(24)38124-8","article-title":"Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.","volume":"289","author":"Linz","year":"1999","journal-title":"J Pharmacol Exp Ther"},{"issue":"2-3","key":"R106-11-20210211","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejphar.2006.11.011","article-title":"Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity.","volume":"557","author":"Izumi","year":"2007","journal-title":"Eur J Pharmacol"},{"issue":"1-3","key":"R107-11-20210211","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejphar.2007.12.015","article-title":"Regulation of intracellular dopamine levels by dopaminergic drugs: involvement of vesicular monoamine transporter.","volume":"582","author":"Izumi","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"R108-11-20210211","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1096\/fj.05-4748fje","article-title":"Patch clamp reveals powerful blockade of the mitochondrial permeability transition pore by the D2-receptor agonist pramipexole.","volume":"20","author":"Sayeed","year":"2006","journal-title":"FASEB J"},{"key":"R109-11-20210211","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2210-10-2","article-title":"Mitochondria-targeted antioxidant effects of S() and R() pramipexole.","volume":"10","author":"Ferrari-Toninelli","year":"2010","journal-title":"BMC Pharmacol"},{"key":"R110-11-20210211","doi-asserted-by":"crossref","first-page":"47053","DOI":"10.1074\/jbc.M303364200","article-title":"Agonist-specific transactivation of phosphoinositide 3-kinase signaling pathway mediated by the dopamine D2 receptor.","volume":"278","author":"Nair","year":"2003","journal-title":"J Biol Chem"},{"key":"R112-11-20210211","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1111\/j.1460-9568.2005.04438.x","article-title":"Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons.","volume":"22","author":"Du","year":"2005","journal-title":"Eur J Neurosci"},{"key":"R113-11-20210211","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/j.1460-9568.2008.06423.x","article-title":"Dopamine D3 receptor-preferring agonists increase dendrite arborization of mesencephalic dopaminergic neurons via extracellular signal-regulated kinase phosphorylation.","volume":"28","author":"Collo","year":"2008","journal-title":"Eur J Neurosci"},{"key":"R114-11-20210211","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neulet.2008.05.067","article-title":"Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity.","volume":"440","author":"Imamura","year":"2008","journal-title":"Neuroci Lett"},{"key":"R115-11-20210211","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.expneurol.2008.04.037","article-title":"Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response.","volume":"212","author":"Iravani","year":"2008","journal-title":"Exp Neurol"},{"key":"R117-11-20210211","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.expneurol.2009.07.013","article-title":"Dopamine receptor activation promotes adult neurogenesis in an acute Parkinson model.","volume":"219","author":"Winner","year":"2009","journal-title":"Exp Neurol"},{"key":"R118-11-20210211","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1592\/phco.29.12.1452","article-title":"Transdermal rotigotine: a clinically innovative dopamine-receptor agonist for the management of Parkinsons disease.","volume":"29","author":"Chen","year":"2009","journal-title":"Pharmacotherapy"},{"key":"R119-11-20210211","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1001\/archneur.64.5.676","article-title":"Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease.","volume":"64","author":"Jankovic","year":"2007","journal-title":"Arch Neurol"},{"key":"R120-11-20210211","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s00702-007-0719-3","article-title":"Continuous delivery of rotigotine decreases extracellular dopamine suggesting continuous receptor stimulation.","volume":"114","author":"Kehr","year":"2007","journal-title":"J Neural Transm"},{"key":"R121-11-20210211","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00210-008-0341-4","article-title":"The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinsons disease.","volume":"379","author":"Scheller","year":"2009","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"R122-11-20210211","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neulet.2007.12.001","article-title":"Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinsons disease.","volume":"432","author":"Scheller","year":"2008","journal-title":"Neurosci Lett"},{"key":"R123-11-20210211","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.expneurol.2006.08.026","article-title":"Rotigotine treatment partially protects from MPTP toxicity in a progressive macaque model of Parkinsons disease.","volume":"203","author":"Scheller","year":"2007","journal-title":"Exp Neurol"},{"key":"R124-11-20210211","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bcp.2003.10.004","article-title":"Dopaminergic D1-like receptor-dependent inhibition of tyrosine hydroxylase mRNA expression and catecholamine production in human lymphocytes.","volume":"67","author":"Ferrari","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"R125-11-20210211","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1046\/j.0953-816x.2000.01443.x","article-title":"Dopamine D(2) receptors regulate tyrosine hydroxylase activity and phosphorylation at Ser40 in rat striatum.","volume":"13","author":"Lindgren","year":"2001","journal-title":"Eur J Neurosci"},{"issue":"Suppl 1","key":"R126-11-20210211","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1002\/mds.22718","article-title":"Protein degradation, aggregation, and misfolding.","volume":"25","author":"Cuervo","year":"2010","journal-title":"Mov Disord"},{"key":"R127-11-20210211","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.parkreldis.2010.04.008","article-title":"Trials of neuroprotective therapies for Parkinsons disease.","volume":"16","author":"Fuente-Fernandez","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 4","key":"R128-11-20210211","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1212\/WNL.66.10_suppl_4.S58","article-title":"Clinical trials aimed at detecting neuroprotection in Parkinsons disease.","volume":"66","author":"Hauser","year":"2006","journal-title":"Neurology"},{"issue":"Suppl 4","key":"R129-11-20210211","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1212\/WNL.66.10_suppl_4.S50","article-title":"Issues in neuroprotection clinical trials in Parkinsons disease.","volume":"66","author":"Kieburtz","year":"2006","journal-title":"Neurology"},{"issue":"suppl 3","key":"R130-11-20210211","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1002\/ana.10488","article-title":"Neuroprotection in Parkinsons Disease: clinical trials.","volume":"53","author":"Stocchi","year":"2003","journal-title":"Ann Neurol"},{"key":"R131-11-20210211","first-page":"587","article-title":"Mendelian forms of Parkinsons disease.","volume":"1792","author":"Gasser","year":"2009","journal-title":"Biochem Biophys Acta"},{"key":"R132-11-20210211","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/mds.23143","article-title":"Rationale for delayed-start study of pramipexole in Parkinsons disease: the PROUD study.","volume":"25","author":"Schapira","year":"2010","journal-title":"Mov Disord"},{"key":"R133-11-20210211","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1474-4422(04)00740-9","article-title":"Challenges in Parkinsons disease: restoration of the nigrostriatal system is not enough.","volume":"3","author":"Lang","year":"2004","journal-title":"Lancet Neurol"},{"key":"R134-11-20210211","first-page":"S255","article-title":"How to judge animal models of Parkinsons disease in terms of neuroprotection.","volume":"70","author":"Hirsch","year":"2006","journal-title":"J Neural Transm"},{"key":"R136-11-20210211","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.tips.2008.10.005","article-title":"Neurobiology and treatment of Parkinsons disease.","volume":"30","author":"Schapira","year":"2008","journal-title":"Trends Pharmacol Sci"}],"container-title":["The Neurologist"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00127893-201111001-00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T14:46:24Z","timestamp":1741877184000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00127893-201111001-00011"}},"subtitle":["Evidence From Animal Models and Clinical Studies"],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":122,"URL":"https:\/\/doi.org\/10.1097\/nrl.0b013e31823968fc","relation":{},"ISSN":["1074-7931"],"issn-type":[{"value":"1074-7931","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}